DOPPS Practice Monitor -- Content Navigator

Filter By: Clinical Topic Facility or Patient Characteristic

+Demographics
- +Age, categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Age, continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Time on dialysis, categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Time on dialysis, continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Gender
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Race
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Ethnicity
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Body-mass index, categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Body-mass index, continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
+Diabetes/Cardiovascular
- +Diabetes as cause of ESRD
  - National sample
- +Diabetes at study entry
  - National sample
- +HbA1c (most recent)
  - +Categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +HbA1c (3 month average)
  - +Categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +HbA1c measurement
  - +Measurement in last 1 month
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Measurement in last 3 months
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Pre-dialysis systolic blood pressure, categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Pre-dialysis systolic blood pressure, continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Aspirin use
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Beta blocker use
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Calcium channel blocker use
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Renin-angiotensin system (RAS) inhibitor use
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Renin-angiotensin system (RAS) inhibitor combination
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Statin use
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Ezetimibe use
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +LDL cholesterol (most recent), categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +LDL cholesterol (most recent), continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +HDL cholesterol (most recent), categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +HDL cholesterol (most recent), continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Triglycerides (most recent), categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Triglycerides (most recent), continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Total cholesterol (most recent), categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Total cholesterol (most recent), continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
+Anemia
- +Hemoglobin (most recent)
  - +All patients, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +All patients, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +ESA-treated pts, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +ESA-treated pts, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Hemoglobin (3 month average)
  - +All patients, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +All patients, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +ESA-treated pts, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +ESA-treated pts, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Erythropoiesis Stimulating Agent (ESA) use
  - +Use in last 1 month
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Use in last 3 months
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Route of administration
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +ESA type
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Weekly IV epoetin dose received
  - +30 day average, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +30 day average, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +90 day average, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +90 day average, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +IV iron use
  - +Use in last 1 month
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Use in last 3 months
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +IV iron type
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Monthly IV iron dose received
  - +30 day average, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +30 day average, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +90 day average, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +90 day average, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Serum ferritin (most recent)
  - +Categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Serum ferritin (3 month average)
  - +Categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Ferritin measurement
  - +Measurement in last 1 month
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Measurement in last 3 months
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Transferrin saturation (most recent)
  - +Categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Transferrin saturation (3 month average)
  - +Categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
+Potassium
- +Serum potassium (most recent)
  - +Categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Serum potassium (3 month average)
  - +Categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Serum potassium measurement
  - +Measurement in last 1 month
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Measurement in last 3 months
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Potassium binder use
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
+Dialysis Prescription and Dose
- +Achieved dialysis session length, categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Achieved dialysis session length, continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Intra-dialytic weight loss (%)
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Prescribed blood flow rate, categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Prescribed blood flow rate, continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Prescribed dialysis sessions per week
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Single-pool Kt/V, categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
- +Single-pool Kt/V, continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
- +Urea reduction ratio >=65%
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
- +Ultrafiltration rate, categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Ultrafiltration rate, continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
+Mineral and Bone Disorder
- +IV vitamin D analog use
  - +Use in last 1 month
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Use in last 3 months
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +IV vitamin D type
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Use with calcimimetics
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
- +Weekly IV vitamin D analog dose received
  - +30 day average, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +30 day average, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +90 day average, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +90 day average, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Oral vitamin D analog use
  - +Oral vitamin D use, last 1 month
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Oral vitamin D use, last 3 months
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Oral vitamin D use with calcimimetics
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
- +Vitamin D analog use
  - +Use in last 3 months
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Vitamin D type
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Route of administration
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Calcimimetics use
  - +Calcimimetic use, last 1 month
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Calcimimetic use, last 3 months
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Calcimimetic type
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Calcimimetic use with vitamin D
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
  - +Etelcalcetide use, last 1 month
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Etelcalcetide use, last 3 months
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Serum calcium (most recent)
  - +Albumin-corrected, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Albumin-corrected, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Total, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Total, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Serum calcium (3 month average)
  - +Albumin-corrected, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Albumin-corrected, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Total, categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Total, continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Serum phosphorus (most recent)
  - +Categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Serum phosphorus (3 month average)
  - +Categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Phosphate binder use
  - +Use in last 1 month
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Use in last 3 months
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Phosphate binder type
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Al- or Mg-containing use in last 3 months
    - National sample
  - +Fe-containing use in last 3 months
    - National sample
- +Serum PTH (most recent)
  - +Categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +Serum PTH (3 month average)
  - +Categories
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Continuous
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +PTH measurement
  - +Measurement in last 1 month
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Measurement in last 3 months
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
- +MBD control
  - +Number of MBD markers out of range
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
  - +Combinations, 2 MBD markers out of range
    - National sample
    - Hospital-based/Free-standing
    - Facility profit status
    - Race (Black/non-Black)
    - Dialysis Organization (DO) Size
    - Incident (<90d)/prevalent (90+d)
+Nutrition
- +Serum albumin (most recent), categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Serum albumin (most recent), continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Serum albumin (3 month average), categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Serum albumin (3 month average), continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Serum creatinine (most recent), categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Serum creatinine (most recent), continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Serum creatinine (3 month average), categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Serum creatinine (3 month average), continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Normalized PCR, categories
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
- +Normalized PCR, continuous
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)
+Vascular Access
- +Vascular access in use
  - National sample
  - Hospital-based/Free-standing
  - Facility profit status
  - Race (Black/non-Black)
  - Dialysis Organization (DO) Size
  - Incident (<90d)/prevalent (90+d)

SHARE